[EEG changes following spirolactone treatment (author's transl)].
EEG studies were done on patients with CNS disease who were treated with d-aldosterone and spirolactone. The baseline EEGs of these patients were found to be slightly abnormal. During infusion of the spirolactone derivative potassium canrenoate a transient deterioration of preexisting EEG disturbances was observed; in addition, bursts of increased muscle activity and transient relative bradycardia were seen. These findings indicate that potassium canrenoate or its lipophilic metabolite canrenone may affect the nervous system directly, possibly via a disturbance in the electrolyte balance. These results are compatible with recent findings in animal studies.
D000450:Aldosterone / Q000494:pharmacology; D001929:Brain Edema / Q000188:drug therapy; D002191:Canrenoic Acid / Q000627:therapeutic use; D004569:Electroencephalography; D004660:Encephalitis / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000503:physiopathology*; D013148:Spironolactone / Q000009:adverse effects*
D013148:Spironolactone; D000450:Aldosterone; D002191:Canrenoic Acid
EEG-Veränderungen nach Spirolacton-Behandlung.